Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

X
Trial Profile

A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Daratumumab (Primary) ; Lenalidomide (Primary) ; Nirogacestat (Primary) ; Pomalidomide (Primary) ; Teclistamab (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Acronyms MajesTEC-2
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 30 Jan 2024 Planned primary completion date changed from 28 Jun 2024 to 31 Oct 2024.
    • 10 Oct 2023 Planned End Date changed from 28 Jun 2024 to 24 Feb 2025.
    • 15 Jun 2023 Preliminary safety (primary objective), efficacy, and PK data presented at the 28th Congress of the European Haematology Association.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top